SKP2 and hepatocellular carcinoma: Furthermore, FASN immunoreactivity was localized in the cytoplasm of HCC cells, whereas malignant hepatocytes exhibited SKP2 immunolabeling in the cytoplasmic and/or nuclear compartments.